1058159-93-5

Upstream product

• 19981-17-0 sodium cyanamide 
• 70987-78-9 (S)-Glycidyl tosylate 

Downstream Products

• 1058159-94-6 toluene-4-sulfonic acid (S)-7-oxo-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1279063-03-4 toluene-4-sulfonic acid (S)-5-ethyl-7-oxo-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1279015-52-9 toluene-4-sulfonic acid (S)-7-oxo-5-pyrrolidin-1-ylmethyl-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1279015-76-7 toluene-4-sulfonic acid (S)-5-(2-fluoroethoxymethyl)-7-oxo-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1279015-74-5 toluene-4-sulfonic acid (S)-7-oxo-5-(tetrahydrofuran-2-ylmethoxymethyl)-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1279015-72-3 toluene-4-sulfonic acid (S)-5-cyclopentyloxymethyl-7-oxo-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1279015-69-8 toluene-4-sulfonic acid (S)-5-isopropoxymethyl-7-oxo-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1279015-66-5 toluene-4-sulfonic acid (S)-5-(2-(tetrahydropyran-2-yloxy)-ethyl)-7-oxo-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1279015-50-7 toluene-4-sulfonic acid (S)-5-morpholinomethyl-7-oxo-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1279015-67-6 toluene-4-sulfonic acid (S)-5-(2-hydroxyethyl)-7-oxo-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1279015-68-7 toluene-4-sulfonic acid (S)-5-ethoxymethyl-7-oxo-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1279015-45-0 toluene-4-sulfonic acid (S)-5-methoxymethyl-7-oxo-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1278585-40-2 toluene-4-sulfonic acid (S)-5-(1,1-difluoro-propyl)-7-oxo-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 
• 1279015-47-2 toluene-4-sulfonic acid (S)-5-cyclopropyl-7-oxo-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-2-ylmethyl ester 

Relevant academic research and scientific papers

SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted dihydro benzocycloalkyl-oxymethyl oxazolopyrimidinones of formula (I) as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds

SUBSTITUTED PARA-BIPHENYLOXYMETHYL DIHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted para-biphenyloxymethyl dihydro oxazolopyrimidinones of formula (I) as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of

SUBSTITUTED PHENOXYMETHYL DIHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted phenoxymethyl dihydro oxazolopyrimidinones of formula (I) defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invent

SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.